TNF-alpha inhibitors for ankylosing spondylitis

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Ankylosing spondylitis is characterized by joint inflammation, pain, and damage.
• Tumor necrosis factor (TNF)-alpha inhibitors target a key protein in the inflammatory cascade.

Purpose of the Study:

• To evaluate the efficacy and safety of adalimumab, etanercept, golimumab, and infliximab in ankylosing spondylitis patients.
• To compare the benefits and harms of these TNF-alpha inhibitors.

Main Methods:

• Systematic review and Bayesian mixed-treatment comparison (MTC) meta-analysis of randomized controlled trials (RCTs).
• Searched multiple databases up to June 2014, including regulatory agency warnings and clinical trial registries.
• Assessed risk of bias and extracted data independently; pooled harms data separately.

Main Results:

• High-quality evidence shows TNF-alpha inhibitors significantly improve ASAS40 response (3-4 times more likely) and physical function compared to placebo.
• Moderate-quality evidence indicates improved ASAS partial remission, with number needed to treat (NNT) ranging from 3 to 11.
• Increased withdrawals due to adverse events were observed (moderate quality evidence), but no significant increase in serious adverse events was detected (low event rates, inconclusive evidence).

Conclusions:

• Anti-TNF agents demonstrate moderate to high-quality evidence for improving clinical symptoms in ankylosing spondylitis.
• Short-term toxicity appears acceptable, with no clear increase in serious adverse events despite higher withdrawal rates.
• Uncertainty remains regarding differences in key benefit or harm outcomes between individual anti-TNF agents due to indirect comparison limitations.